Is LOBEF or ABBV a better dividend investment in 2026?

LOBEF currently yields 3861.00% with a 5% 5-year dividend growth rate. ABBV yields 3.06% with 8.9% growth. The better choice depends on your goal: LOBEF offers higher current income.

What is the dividend yield difference between LOBEF and ABBV?

LOBEF has a forward dividend yield of 3861.00% ($2.00/share annually). ABBV yields 3.06% ($6.65/share annually). The yield gap is 3857.94 percentage points.

Home › Compare › LOBEF vs ABBV

LOBEF vs ABBV: Dividend Comparison 2026

LOBEF yields 3861.00% · ABBV yields 3.06%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 LOBEF wins by $5102776617539.90M in total portfolio value

INVESTMENT

TIME HORIZON10 years

LOBEF

● Live price

3861.00%

Share price

$0.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5102776617540.00M

Annual income

$4,855,397,881,919,778,000.00

Full LOBEF calculator →

ABBV

AbbVie Inc.

● Live price

3.06%

Share price

$217.44

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$102.3K

Annual income

$24,771.77

Full ABBV calculator →

Portfolio growth — LOBEF vs ABBV

📍 LOBEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	LOBEF	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, LOBEF + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

LOBEF pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOBEF

Annual income on $10K today (after 15% tax)

$328,185.33/yr

After 10yr DRIP, annual income (after tax)

$4,127,088,199,631,811,000.00/yr

ABBV

Annual income on $10K today (after 15% tax)

$259.96/yr

After 10yr DRIP, annual income (after tax)

$21,056.00/yr

At 15% tax rate, LOBEF beats the other by $4,127,088,199,631,790,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOBEF + ABBV for your $10,000?

LOBEF: 50%ABBV: 50%

100% ABBV50/50100% LOBEF

Portfolio after 10yr

$2551388308770.05M

Annual income

$2,427,698,940,959,901,000.00/yr

Blended yield

95.15%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LOBEF

No analyst data

Altman Z

-9.3

Piotroski

3/9

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+17.8% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOBEF buys

ABBV buys

No recent congressional trades found for LOBEF or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricLOBEFABBV

Forward yield	3861.00% ✓	3.06%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$5102776617540.00M ✓	$102.3K
Annual income after 10y	$4,855,397,881,919,778,000.00 ✓	$24,771.77
Total dividends collected	$5085877075297.57M ✓	$61.0K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: LOBEF vs ABBV ($10,000, DRIP)

Year	LOBEF Portfolio	LOBEF Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$396,800	$386,100.39	$11,550	$430.00	+$385.3K → LOBEF
2	$14,742,780	$14,318,203.95	$13,472	$627.96	+$14.73M → LOBEF
3	$512,952,973	$497,178,198.17	$15,906	$926.08	+$512.94M → LOBEF
4	$16,715,748,598	$16,166,888,916.48	$19,071	$1,382.55	+$16715.73M → LOBEF
5	$510,255,139,456	$492,369,288,456.53	$23,302	$2,095.81	+$510255.12M → LOBEF
6	$14,592,492,784,652	$14,046,519,785,434.00	$29,150	$3,237.93	+$14592492.76M → LOBEF
7	$391,042,310,644,499	$375,428,343,364,921.60	$37,536	$5,121.41	+$391042310.61M → LOBEF
8	$9,820,789,713,309,148	$9,402,374,440,919,534.00	$50,079	$8,338.38	+$9820789713.26M → LOBEF
9	$231,195,080,018,900,830	$220,686,835,025,660,030.00	$69,753	$14,065.80	+$231195080018.83M → LOBEF
10	$5,102,776,617,540,002,000	$4,855,397,881,919,778,000.00	$102,337	$24,771.77	+$5102776617539.90M → LOBEF

LOBEF vs ABBV: Complete Analysis 2026

LOBEF — Stock

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Full LOBEF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this LOBEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOBEF vs SCHD LOBEF vs JEPI LOBEF vs O LOBEF vs KO LOBEF vs MAIN LOBEF vs JNJ LOBEF vs MRK LOBEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.